

10 February 2026

Osteopore expands into 3D printing services widening value chain and revenue streams

Highlights

- Osteopore's expands value chain capture and revenue streams by offering 3D printing services in Singapore to all public and private hospitals. This expansion has been fuelled by direct demand from hospitals and surgeons.
- 3D printing services include pre-surgical planning models and sterilised, intra-operative use cutting jigs, among others.
- Participation in 3D printing services enables Osteopore to capture a broader portion of the value chain and revenue streams, including digital surgical planning, customised design, additive manufacturing, and clinical collaboration.
- The global healthcare 3D printing market is forecast to reach USD 8.0 billion by the early 2030s, with the Asia-Pacific (APAC) region is expected to be among the fastest-growing markets, with projected CAGRs of approximately 20–22 %, driven by increasing adoption of patient-specific medical devices, expanding surgical volumes, and localisation of advanced manufacturing capabilities¹.

For personal use only

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX; Osteopore or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to announce that the Company is now expanding its services to include a state-of-the-art 3D printing services line, in addition to the current business on craniofacial reconstruction, rhinoplasty, orthopaedic, and dental surgery.

¹ <https://www.precedenceresearch.com/3d-printing-in-healthcare-market?>



This expanded value proposition has the potential to enhance value delivered to the healthcare ecosystem through improved surgical precision, reduced lead times, and more efficient use of hospital resources, while supporting the Company's strategy to diversify revenue streams and participate in higher-value segments of the personalised medical device market.

Osteopore remains focused on its core business areas: craniofacial reconstruction, rhinoplasty, orthopaedic, and dental surgery. The introduction of 3D printing services leverages the Company's capabilities and is a natural extension of its mission to provide innovative and impactful medical solutions. Following the fulfilment of several ad-hoc 3D printing requests from hospital and surgeons, further demand has arisen showing the potential of 3D printing services as a new revenue stream.

The 3D printing services line will support surgeons in visualising complex anatomical structures, facilitating more accurate and effective surgical planning. It also enables the creation of customised cutting jigs tailored to the unique anatomy of each patient, to support a higher level of precision during surgery. These are aimed at reducing surgical time, lowering surgical risks, and enhancing the overall patient experience.

The global healthcare 3D printing market is forecast to grow strongly, with industry estimates indicating expansion from approximately USD 2.0 billion in 2024 to more than USD 8.0 billion by the early 2030s, representing a compound annual growth rate (CAGR) of approximately 18–20 %^{2, 3}.

² <https://www.grandviewresearch.com/press-release/global-healthcare-3d-printing-market>

³ <https://www.precedenceresearch.com/3d-printing-in-healthcare-market>?



The Asia-Pacific (APAC) region is expected to be among the fastest-growing markets, with projected CAGRs of approximately 20–22%, driven by increasing adoption of patient-specific medical devices, expanding surgical volumes, and localisation of advanced manufacturing capabilities.

Participation in 3D printing services enables Osteopore to capture a broader portion of the value chain, including digital surgical planning, customised design, additive manufacturing, and clinical collaboration.

The Company shall update the market on further development in this area accordingly.

Commenting on the establishment of an additional business line, CEO Dr Yujing Lim, said:

"The establishment of this service leverages on our competency in the area of 3D design and printing, and strengthens our network with hospitals, clinics and surgeons, ultimately aiming at improved care for patients.

"We look forward to the positive impact this additional service will have on the broader medical community", said Dr Lim.

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com

For personal use only

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement.

The forward-looking statements in this announcement reflect views held only as of the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their advice before making any investment decision.